OCT 7·SEC EDGARLow
MILNE GEORGE M JR sold $831K of AMLX
MILNE GEORGE M JR sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $27.70 ($0.83M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$AMLX
Amylyx Pharmaceuticals, Inc.
AlphAI earnings readsecond quarter 2026 · AUG 6Amylyx reported second-quarter 2026 net loss of $43.4 million and expects cash runway into 2028 as pivotal Phase 3 LUCIDITY topline data remain anticipated in late August or early September 2026.Verdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $AMLXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AMLX in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $3.8M 11 txs
Mazzariello Gina2× · $310K
10b5-1 share of filings9%
Top stories · $AMLXMore →
OCT 4·marketscreener.com
Certain Restricted Stock Unit of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
OCT 3·finance.yahoo.com
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.
AMLX sentiment & insider activity
Recent AMLX coverage spans financial news, insider activity and corporate actions.
In the last 30 days, AMLX insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($3.8M). The most active reporter was Mazzariello Gina, Chief Legal Officer, with 2 filings. 9% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving AMLX
The insider sale modestly increases supply pressure on AMLX shares.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
Positive trial data may drive the stock higher as investors anticipate regulatory approval and commercial launch.
Analyst upgrades and positive trial data suggest upward pressure on AMLX.
The supply deals lock in cash outlays and create fixed obligations, increasing risk if avexitide uptake is lower than expected.
AlphAI scores every news story that mentions AMLX with an AI model for sentiment and relevance, and aggregates insider trades from Amylyx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AMLX
Score
MILNE GEORGE M JR sold $831K of AMLX
MILNE GEORGE M JR sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $27.70 ($0.83M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readCertain Restricted Stock Unit of Amylyx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-OCT-2026.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
1 min read
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.
2 min readStifel reiterates Amylyx stock rating on avexitide confidence
Stifel maintained a Buy rating and $45 price target for Amylyx (AMLX), citing confidence in avexitide's Phase 3 data and commercial potential. The stock is up 141% YTD. Other analysts raised price targets post-trial results, with a consensus Strong Buy rating. Avexitide showed a 55% reduction vs. placebo in the LUCIDITY trial.
2 min readIs Long Term Avexitide Supply Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?
Amylyx Pharmaceuticals (AMLX) secured long-term supply agreements for avexitide, including a $30M upfront fee. The deals indicate commitment to commercialization but depend on LUCIDITY Phase III trial success. Analysts forecast $343.4M revenue and $86.8M earnings by 2029, with potential 31% upside. Management will discuss plans at a conference in September 2026.
3 min read
Amylyx Stock Tumbles As Rally Meets Dilution Jitters
Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.
2 min readHave Amylyx Pharmaceuticals Insiders Been Selling Stock?
Amylyx Pharmaceuticals' co-founder Joshua Cohen sold $950k worth of stock at $32.16 per share, reducing his holding by 0.9%. This was the largest insider sale in the past year, occurring below the current price of $33.15. Insiders have sold more shares than bought over the past year, with total insider ownership at 6.2% of the company.
1 min read
Amylyx Stock Sinks As Rally Fades And Cash Fears Grow
Amylyx Pharmaceuticals (AMLX) shares declined after a Morgan Stanley event, retreating from 52-week highs. Investors reassess valuation due to manufacturing commitments and capital needs for a 2027 drug launch. Recent rally and public offering raised scrutiny over funding strategy and execution risk. Long-term prospects depend on avexitide's success, but cash burn and reliance on equity offerings pose challenges.
2 min readBedrosian Camille L sold $325K of AMLX
Bedrosian Camille L (Chief Medical Officer) sold 10,028 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.40 ($32.21–$33.09, $0.32M total) across 2 trades on 2026-09-10.
1 min readFRATES JAMES M sold $350K of AMLX
FRATES JAMES M (Chief Financial Officer) sold 10,810 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.36 ($32.27–$33.23, $0.35M total) across 2 trades on 2026-09-10.
1 min read